India's One of the Women Entrepreneur Led Biotechnology Company's New Biosimilar in U.S. Gains Access to Over 100 Million Lives
The has given modest returns of 4.41 per cent over the past year. However, it has declined by 11.93 per cent over the last three years.
Biocon Limited, a leading Indian biotechnology company, has marked a major milestone with the launch of its latest biosimilar, Yesintek™ (ustekinumab-kfce), in the United States. Its subsidiary, Biocon Biologics, has secured market access for this biosimilar through inclusion in the formularies of several major U.S. healthcare providers such as Express Scripts, Cigna, UnitedHealthcare, CVS Health, and Optum Rx. This expanded coverage ensures access to over 100 million lives across the country, reinforcing Biocon’s strategic presence in the Large-Cap U.S. pharmaceutical market.
Yesintek™, a biosimilar to Stelara®, is approved for treating multiple chronic autoimmune diseases, including Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. It offers a cost-effective treatment alternative, aligning with Biocon’s mission to provide affordable healthcare solutions globally. Shreehas Tambe, CEO & Managing Director of Biocon Biologics, highlighted the significance of this development, stating that Yesintek™ is the first product launched in the U.S. as a fully integrated biosimilars company. The biosimilar's approval was based on comprehensive clinical data establishing its equivalence to Stelara® in terms of pharmacokinetics, safety, efficacy, and immunogenicity.
DSIJ's 'Large Rhino' service recommends blue chip stocks of Large Cap companies that have leadership positions in their category. If this interests you, download the service details here.
As of May 5, 2025, Biocon’s stock is trading at Rs 334, jumped over 4 per cent from the previous close. The stock has touched a 52-week high of Rs 396.85 and a low of Rs 291.20, offering modest returns of 4.41 per cent over the past year. However, it has declined by 11.93 per cent over the last three years. The stock’s Price-to-Earnings (PE) ratio stands at 32, indicating a valuation that reflects growth expectations. Biocon currently has a market capitalisation of Rs 38,257 crore, placing it firmly in the Mid-Cap category. One of its notable public shareholders, Arun Suresh Chandavarkar, holds 1.10 per cent stake in the company.
Biocon continues to strengthen its product pipeline through its innovation-led model. Its biosimilars business, Biocon Biologics, has commercialized eight biosimilars and is developing 12 more across key therapeutic areas. The company is not only focused on expanding its global footprint but also advancing its ESG (Environmental, Social, and Governance) goals as part of its broader commitment to sustainable healthcare.
Disclaimer: The article is for informational purposes only and not investment advice.